Predictive Oncology Inc (OQ:POAI)

Business Focus: Medical Equipment, Supplies & Distribution

Apr 30, 2024 04:05 pm ET
Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market, as part of a $6.2 million Phase 2B grant awarded by...
Apr 24, 2024 04:05 pm ET
Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being...
Mar 28, 2024 05:28 pm ET
Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic...
Feb 21, 2024 04:05 pm ET
Predictive Oncology to Participate in Upcoming Investor Conferences
Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will participate in three upcoming investor conferences. Please see below for additional...
Jan 02, 2024 07:00 am ET
Predictive Oncology to Participate in Upcoming San Francisco Conferences
Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will present at the upcoming Biotech Showcase, in San Francisco, CA, on January 9, 2024,...
Nov 14, 2023 07:00 am ET
Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic...
Nov 08, 2023 08:12 am ET
Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital. The objective of the study was to evaluate the use of AI to build...
Nov 07, 2023 07:00 am ET
Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 2023
Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
Aug 10, 2023 05:15 pm ET
Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update
Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic...
Aug 03, 2023 08:00 am ET
Predictive Oncology to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on Thursday, August 10, 2023
Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
Jul 18, 2023 08:00 am ET
Predictive Oncology Announces Relocation of Corporate Headquarters to Pittsburgh
Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
Jun 27, 2023 08:00 am ET
Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board
Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
Jun 20, 2023 08:00 am ET
Predictive Oncology Appoints Dr. Bernard A. Harris, Jr. to its Newly Formed Business Advisory Board
Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
May 23, 2023 08:30 am ET
Predictive Oncology invited to present groundbreaking approach to drug discovery at the 2023 BIO International Convention
Predictive Oncology, Inc. (NASDAQ: POAI) announced today that the company’s Chief Business Officer, Pamela Bush, Ph.D., MBA, will present at the upcoming 2023 BIO International Convention, in Boston, Massachusetts, on June 5, 2023, at 2:45 p.m....
May 15, 2023 05:15 pm ET
Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update
Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic...
May 08, 2023 08:00 am ET
Predictive Oncology to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 15, 2023
Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
May 02, 2023 05:10 pm ET
Predictive Oncology Appoints Pharma, Biotech and Digital Health Veteran Veena Rao, PhD, MBA, to its Board of Directors
Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
Apr 20, 2023 05:10 pm ET
Predictive Oncology Announces Reverse Stock Split
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares. The reverse stock split...
Apr 17, 2023 06:00 pm ET
Predictive Oncology Adjourns Special Meeting of Stockholders
Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
Apr 04, 2023 08:30 am ET
Predictive Oncology Announces Appointment of Oncology Translational Research Leader Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board
Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
Mar 30, 2023 08:30 am ET
Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy
Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announces it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene...
Mar 21, 2023 05:15 pm ET
Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update
Predictive Oncology Inc. (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
Mar 17, 2023 07:00 am ET
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs
Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK (CRUK), today announce that they have partnered to drive...
Mar 16, 2023 05:15 pm ET
Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.01 per...
Mar 14, 2023 08:30 am ET
Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner
Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic...
Mar 09, 2023 08:30 am ET
Predictive Oncology Issues Letter to Shareholders
Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities to accelerate oncologic drug discovery and enable drug development, today issued the following letter...
Feb 23, 2023 08:30 am ET
Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence
Predictive Oncology Inc. (NASDAQ: POAI) and Cvergenx, Inc. today announced an agreement to form a strategic partnership that has the potential to revolutionize the field of radiation oncology with the first-ever genomics-based artificial...
Feb 21, 2023 08:30 am ET
Predictive Oncology launches ACE program to partner with academic and research institutions to advance their drug discovery initiatives
Predictive Oncology Inc. (NASDAQ: POAI) today announced the launch of ACE (Accelerating Compound Exploration), a program to advance the oncology drug development initiatives with academic and research institutions. Predictive Oncology created ACE...
Feb 03, 2023 08:31 am ET
Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology. As a key...
Jan 12, 2023 08:30 am ET
Pioneer of Computational Biology Joins the Scientific Advisory Board of Predictive Oncology
Predictive Oncology Inc. (NASDAQ: POAI) today announced the appointment of Robert F. Murphy, Ph.D., to the company’s Scientific Advisory Board where he will serve alongside other key thought leaders in their respective fields to guide the company’s...
Dec 13, 2022 08:30 am ET
Distinguished Innovator in Genomics Joins the Scientific Advisory Board of Predictive Oncology
Predictive Oncology Inc. (NASDAQ: POAI) today announced the appointment of Marc Malandro, Ph.D., to the company’s Scientific Advisory Board where he will serve alongside other key thought leaders in their respective fields to guide the company's...
Dec 05, 2022 08:30 am ET
Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors
Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company’s strategic initiatives and commercialization efforts....
Nov 10, 2022 05:15 pm ET
Predictive Oncology Reports Third Quarter Financial Results
Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its third quarter ended September 30, 2022, which continue to reflect revenue growth and increased gross profit margin as compared to prior year periods. Highlights...
Oct 25, 2022 08:30 am ET
David S. Smith appointed to the Board of Directors of Predictive Oncology
Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of David S. Smith, JD, to the company’s Board of Directors. Mr. Smith is a life sciences and corporate attorney, veteran biotech industry executive and leading authority on...
Oct 20, 2022 08:30 am ET
Predictive Oncology Announces New Chief Executive Officer Raymond F. Vennare to Lead Company Growth
Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of Raymond F. Vennare as Chief Executive Officer and Chairman of the Board, effective Nov. 1. As an active member on the POAI Board of Directors since September 2021 and,...
Sep 19, 2022 08:30 am ET
Predictive Oncology Strengthens Offerings with GMP Lab and Addition of Leading Expert in Formulation Development
Predictive Oncology (NASDAQ: POAI) today announced several key developments to further strengthen the company’s offerings for pharmaceutical and biotech customers. First is Predictive Oncology’s Good Manufacturing Practices (GMP) lab, which opens...
Sep 16, 2022 05:05 pm ET
Predictive Oncology Announces CEO Retirement
Predictive Oncology (NASDAQ: POAI) today announced that J. Melville (“Mel”) Engle will retire as Chief Executive Officer and as Chairman and a member of the company’s Board of Directors. To ensure a smooth transition of his responsibilities, Mr....
Aug 11, 2022 05:15 pm ET
Predictive Oncology Reports Second Quarter 2022 Financial Results
Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its second quarter ended June 30, 2022, which shows a strong balance sheet with a solid cash balance, commensurate equity and no debt. Highlights from the quarter...
Jul 26, 2022 08:30 am ET
Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansion of its Research and Development Arm
Predictive Oncology (NASDAQ: POAI) today announced a strategic move to further strengthen its business and product offerings by appointing Julia Kirshner, Ph.D., as Chief Scientific Officer. Dr. Kirshner currently serves as Senior Vice President at...
May 18, 2022 05:15 pm ET
Predictive Oncology Announces Closing of $7.2 Million Registered Direct Offerings
Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has closed its...
May 16, 2022 08:55 am ET
Predictive Oncology Announces $7.2 Million Registered Direct Offerings
Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into...
May 12, 2022 05:15 pm ET
Predictive Oncology Reports First Quarter Financial Results
The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predictive Oncology Inc. (NASDAQ: POAI) today, disclosing the results for the quarter ended March...
Apr 26, 2022 08:30 am ET
Marketer with over 20 years of experience selected to head up marketing at Predictive Oncology
Predictive Oncology (NASDAQ: POAI) today announced that Theresa Ferguson has been named Senior Director of Marketing. As Predictive Oncology’s senior marketing leader, Ferguson steps in as the company begins commercialization of its...
Mar 31, 2022 05:25 pm ET
Predictive Oncology Reports Year End 2021 Financial Results and Provides Business Update
Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended December 31, 2021, a period defined...
Mar 24, 2022 08:30 am ET
Predictive Oncology validates Discovery 21 proof-of-concept campaign
Predictive Oncology (NASDAQ: POAI) achieved a key milestone toward monetizing its unique approach to leverage artificial intelligence (AI) in oncology drug discovery. Earlier this year, Predictive Oncology’s Discovery 21 proof-of-concept campaign...
Jan 27, 2022 07:30 am ET
Predictive Oncology set to market AI drug discovery platform
Predictive Oncology Inc. (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will grow to $20 billion in the next three years, reported the Company today in outlining its...
Jan 13, 2022 08:30 am ET
POAI Reports Strong Results From Its AI Cancer Drug Evaluation  
Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial Intelligence (AI) program CoRE™...
Dec 27, 2021 05:10 pm ET
Predictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021
Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Annual Meeting of Stockholders was convened at 3:00...
Dec 21, 2021 08:30 am ET
Predictive Oncology – Year-end Shareholder Update!
Predictive Oncology, (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, is moving in the right direction. In November 2021, POAI acquired zPREDICTA, a cutting edge cancer...
Dec 07, 2021 08:30 am ET
Pamela Bush, Ph.D., MBA, Joins Predictive Oncology as SVP of Strategic Sales and Business Development
Predictive Oncology, (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, today announced that Pamela Bush, Ph.D., MBA would be joining the company’s leadership team as SVP of...
Dec 01, 2021 08:30 am ET
Predictive Oncology Acquires zPREDICTA, Inc.
Predictive Oncology, (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, today announced the acquisition of zPREDICTA, a company pioneering tumor-specific in vitro 3D cell...
Nov 10, 2021 05:15 pm ET
Predictive Oncology Reports Third Quarter Financial Results
Results from the third quarter show strong potential for future growth, said Predictive Oncology (Nasdaq: POAI) today, announcing financial results for the quarter ended September 30, 2021. All three of Predictive Oncology’s reportable segments...
Oct 19, 2021 08:30 am ET
Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research Advancements
Predictive Oncology, an oncology and cancer research company using big data and machine learning to improve pharmaceutical development and predictive treatment outcomes, launched a website today that emphasizes its role in advancing its mission....
Sep 24, 2021 08:31 am ET
Thinking about buying stock in Capricor Therapeutics, vTv Therapeutics, Li-Cycle Holdings, Predictive Oncology, or Rewalk Robotics?
NEW YORK, Sept. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, VTVT, LICY, POAI, and RWLK.
Sep 22, 2021 08:30 am ET
Thinking about buying stock in Aethlon Medical, Innate Pharma, Predictive Oncology, Bridgeline Digital, or Aterian?
NEW YORK, Sept. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, IPHA, POAI, BLIN, and ATER.
Sep 15, 2021 08:30 am ET
Predictive Oncology Inc. Announces Newest Board Member
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that Raymond F. Vennare was elected to the Board of Directors,...
Aug 18, 2021 01:45 pm ET
Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting
Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that on August 17, 2021, the stockholders approved an amendment to the...
Aug 11, 2021 05:15 pm ET
Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update
Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2021, and provided an...
Aug 11, 2021 08:30 am ET
Predictive Oncology Adjourns Special Meeting of Stockholders
Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Special Meeting of Stockholders, which was convened at...
Aug 03, 2021 08:30 am ET
Predictive Oncology subsidiary, Helomics uses data from the 100,000 Genomes Project to better predict ovarian cancer outcomes
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to report initial results on AI-driven models of ovarian cancer. POAI...
Jun 22, 2021 08:30 am ET
Predictive Oncology Inc.’s Subsidiaries Soluble Biotech Inc. and TumorGenesis Inc. are both constructing new GMP labs
Predictive Oncology (NASDAQ: POAI), an AI-driven oncology and drug discovery company, announced today that two of their wholly owned subsidiaries, Soluble Biotech Inc. and TumorGenesis Inc. are both expanding their unique services by completing the...
Jun 18, 2021 09:30 am ET
Predictive Oncology Announces Closing of $21.34 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the closing...
Jun 14, 2021 09:30 am ET
Predictive Oncology Announces $21.34 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into...
Jun 02, 2021 08:30 am ET
Predictive Oncology Inc. to Attend BIO DIGITAL, the World’s Largest Biotech Partnering Experience
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its three wholly owned subsidiaries, Helomics, TumorGenesis and...
May 20, 2021 08:30 am ET
Predictive Oncology Inc.’s Wholly Owned Subsidiary, TumorGenesis, Partners with Cellevate AB
Predictive Oncology (NASDAQ: POAI), an artificial intelligence driven oncology and drug discovery company, announced today that its wholly owned subsidiary, TumorGenesis (TumorGenesis.net), has partnered a deal with the Swedish firm Cellevate AB...
May 12, 2021 05:20 pm ET
Predictive Oncology Reports Financial Results for Quarter Ended March 31, 2021 and Provides Business Update
Predictive Oncology Inc. (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended March 31, 2021 and provided...
Apr 27, 2021 08:30 am ET
Predictive Oncology Inc. Announces Newest Board Member
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce today their newest Board Member Dr. Christina Jenkins. Dr....
Apr 21, 2021 08:17 am ET
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc.
via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as...
Apr 21, 2021 08:17 am ET
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc.
(via InvestorWire) InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as...
Mar 23, 2021 08:30 am ET
Predictive Oncology Inc. Announces New CEO
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is excited to announce today that they have appointed J. Melville (“Mel”) Engle as Chief...
Mar 15, 2021 05:15 pm ET
Predictive Oncology Reports Year End 2020 Financial Results, Provides Business Update
Predictive Oncology (NASDAQ: POAI) – Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended...
Mar 08, 2021 08:30 am ET
Predictive Oncology’s, Skyline Medical Division, Developing Generation 3 Direct-to-Drain Automated Fluid Waste Management System
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its Skyline Medical Division is renewing developing a new Generation...
Feb 24, 2021 08:30 am ET
POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian Cancer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce today that it has completed key data generation milestones in its...
Feb 23, 2021 05:30 pm ET
Predictive Oncology Announces Closing of $17.6 Million Private Placement Priced At-the-Market
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its...
Feb 18, 2021 09:00 am ET
Predictive Oncology Announces $17.6 Million Private Placement Priced At-the-Market
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today that it has entered into securities...
Feb 17, 2021 08:30 am ET
Two Top Researchers find Breakthrough Discoveries using Predictive Oncology’s Wholly Owned Subsidiary, TumorGenesis’s Technology
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the products of its wholly owned subsidiary, TumorGenesis, aided...
Feb 16, 2021 05:00 pm ET
Predictive Oncology Announces Closing of $7.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its...
Feb 11, 2021 12:30 am ET
Predictive Oncology Announces $7.4 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into...
Feb 08, 2021 08:30 am ET
Predictive Oncology’s Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground-breaking PeDAL™ platform for ovarian cancer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that it will start an in-house drug repurposing project, focused on...
Feb 02, 2021 12:00 pm ET
Predictive Oncology Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that based on a...
Feb 02, 2021 08:30 am ET
Litchfield Hills Research Rates Predictive Oncology a Buy on Recent Analyst Report
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that equity research firm, Litchfield Hills Research LLC, released its...
Jan 28, 2021 08:30 am ET
Soluble Biotech, a Wholly Owned Subsidiary of Predictive Oncology, Inked Contract with Large Pharmaceutical Company
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary Soluble Biotech, Inc. just inked another...
Jan 26, 2021 09:00 pm ET
Predictive Oncology Announces Closing of $4.1 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its...
Jan 22, 2021 08:00 am ET
Predictive Oncology Announces $4.1 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into...
Jan 21, 2021 05:25 pm ET
Predictive Oncology Announces Closing of $2.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its...
Jan 19, 2021 08:00 am ET
Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into...
Jan 14, 2021 08:30 am ET
Predictive Oncology Reports That Its Wholly Owned Subsidiary, TumorGenesis, Has Sold Media to Two Top Research Medical Centers
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary TumorGenesis, Inc. in the last quarter...
Jan 12, 2021 05:15 pm ET
Predictive Oncology Announces Closing of $3.074 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its...
Jan 08, 2021 09:00 am ET
Predictive Oncology Announces $3,074,007 Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into...
Jan 06, 2021 08:30 am ET
Predictive Oncology’s Wholly Owned Subsidiary Helomics completes integration of Quantitative Medicine
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary Helomics has completed the integration...
Jan 05, 2021 08:30 am ET
Predictive Oncology Hires Investor Relations Firm
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to announce that it has engaged Landon Capital to provide investor relations...
Dec 29, 2020 05:15 pm ET
Predictive Oncology Announces Cancellation of Special Meeting in December 2020
Predictive Oncology (NASDAQ: POAI) (the “Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Board of Directors has decided to cancel its...
Dec 09, 2020 08:30 am ET
Predictive Oncology Sends Letter to Shareholders Regarding Special Meeting to be Reconvened on December 30, 2020
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual Special Meeting of...
Dec 02, 2020 08:00 am ET
Predictive Oncology Announces Adjournment of Special Meeting
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its virtual Special Meeting of Stockholders, scheduled for December...
Nov 16, 2020 05:20 pm ET
Predictive Oncology Reports Third Quarter 2020 Financial Results, Provides Business Update
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended September 30, 2020 and provided a...
Oct 27, 2020 08:30 am ET
Predictive Oncology Inc. CEO Provides Updates on Subsidiaries, Highlights Recent Milestones and Near-Term Goals
via NetworkNewsAudio — Predictive Oncology Inc. (NASDAQ: POAI) today announces that its chief executive officer, Carl Schwartz, has been featured in an exclusive audio interview with NetworkNewsWire (“NNW”), a financial news and content...
Oct 06, 2020 08:30 am ET
Predictive Oncology CEO Letter to Shareholders
Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to release the CEO’s letter to the shareholders. To our valued shareholders,...
Sep 22, 2020 05:10 pm ET
Predictive Oncology Secures License for an Additional 71 Unique Ovarian Cancer Cell Lines from Ximbio, Cancer Research UK’s Premier Reagents Distributor
TumorGenesis, a division of Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to announce that it has received a license for an...
Sep 01, 2020 05:15 pm ET
Predictive Oncology Inc to Present at LD Micro's "LD 500" Virtual Investor Conference on Wednesday, September 02, 2020 3:40 PM Eastern Time
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that management, will present at the LD Micro's "LD 500" Virtual Investor...
Aug 31, 2020 05:00 pm ET
(LD Micro) 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 20, 2020 08:30 am ET
Soluble Biotech Announces First Contract with a Major Pharmaceutical Company for Protein Expression and Solubility Studies
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that its Soluble Biotech division, a provider of soluble and...
Aug 18, 2020 08:30 am ET
Predictive Oncology’s Skyline Medical Sells 8 STREAMWAY® Systems to a Large University Hospital Organization in Virginia; 13 STREAMWAY® Systems Sold Halfway Into Q3 2020
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that its Skyline Medical division, producer of the FDA-approved...
Aug 14, 2020 08:30 am ET
Predictive Oncology Announces DojoLIVE! Interview with Helomics CIO Mark Collins, ‘Can We Cure Cancer with Artificial Intelligence?’
via NetworkWire — Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Mark Collins, Ph.D., chief innovation officer...
Aug 13, 2020 05:10 pm ET
Predictive Oncology Reports Second Quarter 2020 Financial Results, Provides Business Update
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2020 and provided a...
Aug 11, 2020 08:30 am ET
Predictive Oncology Issues Letter to Shareholders
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today issued a letter to shareholders discussing the Company’s recent accomplishments and...
Aug 05, 2020 09:00 am ET
LD Micro Announces Preliminary List of Presenters for the LD-500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Jul 14, 2020 08:30 am ET
Predictive Oncology Refreshes Board with Appointment of Three New Directors
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of three new members to the company’s board of directors,...
Jul 07, 2020 08:15 am ET
Predictive Oncology Completes Acquisition of Quantitative Medicine
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a...
Jun 29, 2020 04:30 pm ET
Predictive Oncology Inc. Announces Receipt of Cash Proceeds of $2.2 Million from Exercise of Warrants
Predictive Oncology Inc. (the “Company,” “Predictive Oncology,” “we,” “our” or “us”) (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the...
Jun 18, 2020 08:30 am ET
Predictive Oncology’s TumorGenesis Division Secures First Commercial Sale of its Novel Ovarian Cancer Cell Media
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, today announces that Predictive’s TumorGenesis division sold...
Jun 08, 2020 04:15 pm ET
Predictive Oncology Reports First Quarter 2020 Financial Results, Provides Business Update
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended March 31, 2020 and provided a...
Jun 02, 2020 08:30 am ET
Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech
Predictive Oncology Inc. (NASDAQ: POAI) (the “Company”) a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the acquisition of the assets of...
May 14, 2020 08:30 am ET
Predictive Oncology (NASDAQ Symbol POAI) is licensing and partnering this groundbreaking NSP10 technology in the race to develop a vaccine for development
Predictive Oncology (NASDAQ: POAI)  has, with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter, entered the...
May 07, 2020 08:00 am ET
Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into...
May 06, 2020 08:30 am ET
Predictive Oncology and Dr. Daniel Carter Collaborating to Develop a Potential COVID-19 Vaccine Utilizing Novel Nanoparticle Vaccine Platform, Based on NSP-10
Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter, entered the race to...
Apr 22, 2020 05:00 pm ET
Predictive Oncology Exchanges $2.1 Million of Debt for Equity, Streamlining Capital Structure and Simplifying Balance Sheet
Predictive Oncology (NASDAQ: POAI) today announced that it has entered into an Exchange Agreement relating to a $2.1 million promissory note of the Company with Dr. Carl Schwartz, the company’s Chief Executive Officer. Under the agreement, Dr....
Apr 22, 2020 08:30 am ET
Predictive Oncology (NASDAQ: POAI) CEO Discusses ‘Major Asset’ in Exclusive Interview
via NetworkNewsAudio — Predictive Oncology (NASDAQ: POAI) today announces that Company director and CEO Dr. Carl Schwartz, in an interview with NetworkNewsWire (NNW), discussed the Predictive Oncology’s distinctive business model and significant...
Apr 01, 2020 08:45 am ET
Predictive Oncology Reports 2019 Full-year Financial Results
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for its...
Mar 31, 2020 08:30 am ET
POAI Subsidiary Helomics Continues Progress Towards Goal of Developing an AI-Driven Predictive Model of Ovarian Cancer
Predictive Oncology Inc. (NASDAQ: POAI) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced continued progress towards by its Helomics...
Mar 23, 2020 08:00 am ET
Predictive Oncology Inc. Announces Completion of $3.5 Million Private Placement
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for...
Mar 16, 2020 09:00 am ET
Predictive Oncology Inc. Announces $3.5 Million Private Placement
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for...
Mar 12, 2020 08:30 am ET
Predictive Oncology Launches New AI Platform for Vaccine and Drug Development Targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS)
Predictive Oncology Inc. (NASDAQ: POAI) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces it will launch a new AI platform for...
Mar 02, 2020 08:30 am ET
Predictive Oncology Provides Acquisition Update, Stresses Importance of AI in New Anti-Cancers, Anti-Virals and Vaccines
Amid mounting concern over the impact of the COVID-19 outbreak, caused by the novel coronavirus 2019-nCoV, governments, universities and companies are racing to develop new diagnostics, vaccines and drug therapies to battle the disease. Artificial...
Feb 21, 2020 08:30 am ET
Predictive Oncology Inc. Appoints Dan Handley, M.S., Ph.D. to Board of Directors
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for...
Feb 05, 2020 08:30 am ET
Predictive Oncology Launches Innovative Specialty Media for Growing Ovarian Tumors in the Lab
TumorGenesis, Inc. a subsidiary of Predictive Oncology, Inc. (NASDAQ: POAI) has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor of its innovative culture media for growing ovarian tumor cells. Unlike...
Jan 24, 2020 12:30 pm ET
Predictive Oncology Inc. Signs Letter of Intent to Acquire Quantitative Medicine (qtmed.com) and an AI Engine™ (CoRE™) that Facilitates Accelerated Drug Discovery and Development
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces it has signed a letter of...
Jan 06, 2020 09:00 am ET
Predictive Oncology Inc. Appoints Pam Prior to Board of Directors
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for...
Dec 17, 2019 08:30 am ET
Predictive Oncology Inc. Announces Extension Of Promissory Note Due December 31, 2019
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for...
Dec 09, 2019 08:30 am ET
Predictive Oncology Provides Updates on Commercialization of Its Cancer Quest 2020 Initiative
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for...
Dec 05, 2019 08:30 am ET
Predictive Oncology Confirms Indications of Interest for Skyline Medical Business
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has received indications of interest from...
Nov 25, 2019 08:30 am ET
Predictive Oncology Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that based on a notification letter (the “Notification...
Nov 20, 2019 08:30 am ET
Predictive Oncology Secures $15,000,000 Equity Line
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it entered into a $15 million common stock...
Nov 19, 2019 08:30 am ET
Predictive Oncology CEO Discusses Corporate Milestones, Unique Approach to Cancer Research in Exclusive Broadcast
via NetworkNewsAudio – Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery, today announces the broadcast of...
Nov 15, 2019 05:10 pm ET
Predictive Oncology Inc. Reports Q3 Results; Revenues Increase 58%
Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through...
Nov 07, 2019 08:30 am ET
Predictive Oncology Featured in Broadcast Evaluating Targeted Cancer Therapies, Higher Survival Rates
via NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) announces the availability of a broadcast titled, “New Hope in the Battle Against Ovarian Cancer.” To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/L4Kxb To read the full...
Nov 06, 2019 08:30 am ET
Predictive Oncology Featured in Publication Discussing the Impact of Artificial Intelligence on Cancer Treatment
via NetworkWire — Predictive Oncology (NASDAQ: POAI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full...
Oct 31, 2019 08:30 am ET
Predictive Oncology (NASDAQ: POAI) Featured in Broadcast on Big Data, AI’s Potential to Fight Cancer
via NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) announces the availability of a broadcast titled, “Delivering Precision Medicine’s True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics.” To hear the...
Oct 31, 2019 08:30 am ET
Predictive Oncology Reaches First Milestone in Building AI-driven Predictive Models of Ovarian Cancer
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that its Helomics subsidiary has begun to sequence...
Oct 30, 2019 08:30 am ET
Predictive Oncology (NASDAQ: POAI) Featured in NetworkNewsWire Publication Discussing Power of Data Plus AI in Precision Medicine
via NetworkWire — Predictive Oncology (NASDAQ: POAI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full...
Oct 24, 2019 08:30 am ET
Predictive Oncology: Helomics to present initial findings from its analysis of UK 100,000 Genomes Project data towards its goal of building AI-driven predictive models of ovarian cancer
Predictive Oncology (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Helomics CTO Dr. Mark Collins will speak...
Oct 02, 2019 09:57 am ET
Skyline Medical, a Division of Predictive Oncology Inc. (POAI), Sells 10 STREAMWAY® Systems to Prominent Teaching Hospital
Predictive Oncology Inc. (NASDAQ: POAI), today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY® System for automated, direct-to-drain medical fluid disposal, has completed the sale of ten systems to...
Oct 02, 2019 08:27 am ET
Predictive Oncology Inc. Announces Pricing of Public Offering of Up to $3,167,768.50 of Common Stock
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced the pricing of its previously announced public offering of its common stock, with anticipated gross proceeds of up to $3,167,768.50, before deducting placement...
Oct 02, 2019 08:00 am ET
Predictive Oncology Inc. (POAI) Sells 10 STREAMWAY® Systems to Prominent Teaching Hospital
Predictive Oncology Inc. (NASDAQ: POAI) today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY® System for automated, direct-to-drain medical fluid disposal, has completed the sale of ten systems to...
Oct 01, 2019 05:45 pm ET
Predictive Oncology Inc. Announces Proposed Public Offering of Common Stock
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the...
Sep 30, 2019 01:00 pm ET
Predictive Oncology Inc. Announces Repayment or Extension of Promissory Notes due September 28, 2019
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced that its secured promissory notes that were due September 28, 2019 have been repaid or extended. On September 27, 2019, the Company repaid the remaining...
Sep 19, 2019 08:30 am ET
Coverage Initiated for Predictive Oncology via NetworkNewsWire
via NetworkWire – Predictive Oncology (NASDAQ: POAI), an innovative company focused on the use of data and artificial intelligence (AI) to develop personalized cancer therapies and improve patient outcome, today announces it has selected the...
Aug 19, 2019 05:15 pm ET
Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through...
Aug 19, 2019 08:00 am ET
Predictive Oncology to Report Second Quarter 2019 Financial Results and Provide Company Update on Monday, August 19, 2019
Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through...
Aug 15, 2019 05:00 pm ET
Predictive Oncology to Report Second Quarter 2019 Financial Results and Provide Company Update on Monday, August 19, 2019
Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through...
Aug 06, 2019 08:00 am ET
Predictive Oncology’s Skyline Medical Division Expands Its Asian Market Share with First-Ever Orders of STREAMWAY Systems in India
Predictive Oncology, Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), today announced its Skyline Medical division has received its first order from India for four machines to be sold to local hospitals. “The sale of these four...
Jul 30, 2019 08:00 am ET
Predictive Oncology Subsidiary Helomics Executes Next Phase of Agreement with Interpace to Enhance the Diagnosis of Thyroid Cancer via AI-Driven Models
Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today its Helomics division has executed on an agreement...
Jul 18, 2019 08:00 am ET
Predictive Oncology Subsidiary Helomics Collaborates with UPMC to Establish a Data and Artificial Intelligence-Driven Approach to Treating Ovarian Cancer
Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven...
Jul 18, 2019 06:55 am ET
Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial...
Jun 26, 2019 08:00 am ET
Predictive Oncology Subsidiary, Helomics, Signs Collaborative Research Agreement with ChemImage to Expand Personalized Medicine to Prostate Cancer Prognosis and Treatment
Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has signed a collaborative research agreement with...
Jun 12, 2019 08:00 am ET
Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Officer of Helomics
Predictive Oncology Inc. (Nasdaq: AIPT) (“Predictive Oncology” or the “Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has appointed Amelia Warner, Pharm.D., RPh, as...
Jun 11, 2019 08:00 am ET
Precision Therapeutics Announces Corporate Name Change To Predictive Oncology Inc.
Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has changed its corporate name to Predictive...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.